LEGEND: A phase 1/2 study of detalimogene voraplasmid (EG-70), an intravesical monotherapy for patients with high-risk non–muscle-invasive bladder cancer (NMIBC).

Authors: Jen-Jane Liu, Raj Satkunasivam, Rian J. Dickstein, Shreyas Joshi, Sam S. Chang, Gautam Jayram, Neal D. Shore, Yair Lotan, Anne K. Schuckman, Raj Pruthi, Anthony Cheung, Katherine Hubert Chan, Christine Tosone, Scott Johnson, Vignesh Packiam, Christine Ibilibor, Wassim Kassouf, Ashish M. Kamat, John Arthur Taylor, Gary D. Steinberg

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4631

Source: Full article

---

Abstract

TPS4631